NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors

Documenti analoghi

• Microscopically Positive Margins for Primary Gastrointestinal Stromal Tumors: Analysis of Risk Factors and Tumor Recurrence
  di: McCarter, Martin D, et al.
  Pubblicazione: (2012)
• Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor (GIST): ACOSOG Z9000 (Alliance) intergroup phase 2 trial
  di: DeMatteo, Ronald P., et al.
  Pubblicazione: (2013)
• Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial
  di: Raut, Chandrajit P., et al.
  Pubblicazione: (2018)
• Placebo-Controlled Randomized Trial of Adjuvant Imatinib Mesylate Following the Resection of Localized, Primary Gastrointestinal Stromal Tumor (GIST)
  di: DeMatteo, Ronald P., et al.
  Pubblicazione: (2009)
• Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated with Tyrosine Kinase Inhibitors: A Two Institutional Analysis
  di: Fairweather, Mark, et al.
  Pubblicazione: (2018)